Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands

Phase 4CompletedNCT01910831

The Center for Clinical and Cosmetic Research20 enrolled

Overview

To determine the efficacy (measured at 12 weeks) of DerMend Moisturizing Bruise Formula in improving the appearance of bruising and reducing the appearance of photoaging of the forearms and hands in mature skin. Assessments will be made through ongoing objective measurements and clinical ratings. To confirm the safety (local tolerance) of DerMend Moisturizing Bruise Formula.

Twenty subjects with mature skin, at one study center, with bruising and moderate to severe photodamage will be selected for the study. Twenty subjects will be enrolled to achieve a total of 40 arms to be analyzed. At baseline, the Subject will be instructed to use the study cream on one forearm and hand while a control cream will be used on the other. Both the study cream and the control cream will be provided in containers labeled Left and Right so that the subjects are blinded. Each cream labeled Left and Right will be randomized with either the treatment or control cream in the Left container and the opposite cream will be assigned to the Right container. Each subject will always get the control cream in one container and the treatment cream in the other container. Each subject will be randomized to apply cream Right to the right forearm and hand. Subject will apply cream Left to the left forearm and hand. At each visit, the Evaluator will count the total number of bruises, determine the size of each bruise and assess each forearm and hand for surface roughness, laxity and mottled hyperpigmentation. Furthermore, subjective investigator and subject global assessments of bruising, skin roughness, wrinkling and pigmentation will be measured. Subjects will be evaluated at weeks 0 (baseline), 2, 4, 6, 8, 10, and 12. Additionally, standardized, high-resolution digital photographs will be taken at each visit using the Vectra software.. The following scales will be used for grading these features: Roughness (degree of scaling and surface texture) - very smooth (1), mostly smooth (2), slightly rough (3), rough (4), very rough (5). Laxity (ability to spring back after pinching the skin) - very tight (1), somewhat tight (2), somewhat loose (3), loose (4), very loose (5). Mottled hyperpigmentation (a combination of lentigines and hyperpigmented and hypopigmented spots) - very even (1), mostly even with few blotches (2), blotchy (3), mostly blotchy (4), very blotchy (5). Secondary endpoints will be measured including the speed of healing (measured by the two week average percentage change in bruising) and a reduction in the Investigator's and Subject's Global Assessment compared to baseline after twelve weeks. The following 5-point scale will be used for both the Investigator's and Subject's Global Assessments: 0, no improvement; 1, \<25% improvement; 2, 25% to 50% improvement; 3, 51% to 75% improvement; and 4, \>75% improvement. Finally, adverse events, including but not limited to redness, swelling, blistering, ulceration, bleeding, itch or pain, will be monitored at each visit and assessed by both the Subject and the Evaluator.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Purpura

Interventions

DerMend Moisturizing Bruise FormulaDRUG

DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.

Non-active placebo controlDRUG

Non-active placebo control

Eligibility

Sex: ALLMin age: 60 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients who meet all of the following criteria are eligible for this study: 1. Male and female subjects who are 60-80 years of age, with phototypes I to IV. 2. Subjects who have provided written, informed consent. 3. Subjects with multiple bruises on both forearms and hands. 4. Subjects with moderate to severe photodamage on forearms and hands. 5. Subjects with relatively equal photodamage on both forearms and hands. 6. Subjects who are willing to follow the treatment schedule. 7. Subjects who are willing to maintain their usual sunscreen or use of photoprotective clothing during outdoor activities. Exclusion Criteria: Patients who meet any of the following criteria are not eligible for this study: 1. Participation in a clinical drug or device research study within 30 days of enrollment or participation in a research study concurrent with this study; 2. Subjects with history of bleeding disorders; 3. Subjects with use of isotretinoin in the past 12 months; 4. Subjects with a pacemaker or internal defibrillator; 5. Subjects who take more than 2 anticoagulant therapies. 6. Treatment of any type of cancer within the last 6 months; 7. Subjects who are unable to communicate or cooperate with the Investigator due to language problems, poor mental development, or impaired cerebral function; 8. History of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure, including known sensitivities to any ingredient; 9. Concomitant use of potentially irritating over-the-counter products that contain ingredients such as arnica, alpha-hydroxy acid, salicylic acid, retinol or glycolic acid; 10. Subjects who present with one or more conditions which, in the opinion of the investigator, making the subject unsuitable for participation. 11. Subjects who apply any topicals other than the study treatment or their usual sunscreen.

Locations (1)

Center for Clinical and Cosmetic Research

Aventura, Florida, United States

Outcomes

Primary Outcomes

Reduction of Bruising

Time frame: 12 weeks

Secondary Outcomes

Investigator Global Assessment (IGA)

To determine efficacy with respect to the IGA of improving the appearance of "bruising" and reducing the appearance of photoaging of the forearms and hands: IGA: 0=No improvement 1. \<25% improvement 2. 25% to 50% improvement 3. 51% to 75% improvement 4. \>75% improvement

Time frame: 12 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.